Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $15.12
Volume
95.43 K
Value Traded
849.40 K
Short % Float
3.03%
+8.24%Week
-18.43%1 Month
-32.47%3 Month
-53.19%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.68 M
EPS (TTM)
-7.03
P/E Ratio
-
Ent. Value
-5.92 M
Total Shares
4.47 M
Float Shares
4.34 M
Insiders
2.83%
Institutions
8.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BJDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Bluejay Diagnostics, Inc.
Past FDA Catalysts and PDUFA Decisions
How BJDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Bluejay Diagnostics, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BJDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Symphony™ IL-6 Test | sepsis and septic shock | 2026-10-06 | total patients: 777; 28 day mortality rate: 18%; 28 day survivors: 637; 28 day non survivors: 140; septic shock non survivors: 56.4%; septic shock survivors: 35.8%; bacterial infection: 84.0%; positive blood culture: 32.4%; infection likely: 86.5%Read More | Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic ShockRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -34,938 92,055 held | $1.40 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BJDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BJDX for Q2 2026. | ||||
BJDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BJDX ranks across every disease it competes in
Competitive Position is a premium feature
See how BJDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBJDX News
BJDX▲ +6.5%on this news
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Bluejay Diagnostics announced significant findings from the SYMON-II clinical validation study, which evaluates IL-6 as a biomarker for mortality risk in sepsis. The study involved 777 patients, revealing an 18% mortality rate and highlighting the importance of timely information for clinicians. The Symphony™ IL-6 Test aims to provide rapid results, but it is not yet FDA approved.
Read more →BJDX▲ +23.7%on this news
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Bluejay Diagnostics has formed a strategic partnership with Lovell Government Services to enhance access to the U.S. federal healthcare market. This collaboration aims to establish a distribution and marketing framework for Bluejay's Symphony™ diagnostic platform, pending FDA clearance. Lovell will act as the exclusive distributor for federal procurement opportunities, facilitating Bluejay's entry into significant government-operated healthcare systems.
Read more →BJDXBluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Bluejay Diagnostics reported its Q2 2026 results, highlighting the completion of patient enrollment in the SYMON-II pivotal clinical study with 750 patients. The company is advancing towards a planned FDA 510(k) submission, supported by a recent manufacturing contract. Bluejay ended the quarter with approximately $9.6 million in cash, bolstering its financial position for upcoming regulatory and commercialization efforts.
Read more →BJDXBluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics has successfully completed patient enrollment in its SYMON-II clinical validation study, achieving its target of 750 patients earlier than expected. This study aims to evaluate the Symphony IL-6 test's ability to assess 28-day mortality risk in sepsis patients. Preliminary data indicates a significant mortality rate, which may support future regulatory submissions and commercialization efforts.
Read more →BJDX▲ +9%on this news
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics has successfully closed a private placement raising $23.7 million, which includes $8.5 million upfront and potential additional proceeds of $15.2 million from warrants. The net proceeds are expected to extend the company's cash runway into the first quarter of 2027, aiding in FDA submission and commercialization efforts. The offering was facilitated by H.C. Wainwright & Co.
Read more →BJDX▼ -15.6%on this news
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics has announced a private placement expected to raise $8.5 million, with potential additional proceeds of approximately $15.1 million from warrants. The net proceeds are anticipated to extend the company's cash runway into the first quarter of 2027, supporting their FDA submission and other research activities. The offering is set to close on June 3, 2026, pending customary conditions.
Read more →BJDX▲ +100%on this newsshared move
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics has formed a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform. This collaboration aims to establish scalable U.S.-based manufacturing capabilities, enhancing supply chain resilience and reducing reliance on overseas production. The partnership is expected to support Bluejay's clinical development and commercialization efforts for its near-patient diagnostic solutions.
Read more →BJDXBluejay Diagnostics Provides First Quarter 2026 Corporate Update
Bluejay Diagnostics provided an update on its progress in Q1 2026, focusing on advancements in the Symphony IL-6 test for sepsis. The company reported a successful enrollment of around 680 patients in its SYMON-II pivotal clinical study, aiming for a total of 750 participants. Additionally, Bluejay has resolved manufacturing issues and is preparing for regulatory submissions. With financial management in focus, Bluejay is navigating its objectives towards future commercialization opportunities.
Read more →BJDXBluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Bluejay Diagnostics has successfully enrolled 624 patients in its SYMON-II pivotal clinical trial, which aims to evaluate the Symphony™ platform for IL-6 testing in critical care settings. The trial is nearing its target enrollment of 750 patients, expected to be completed in the next 2 to 3 months. The study's criteria have not significantly excluded patients, indicating effective recruitment.
Read more →BJDXBluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
Bluejay Diagnostics announced that its abstract on the Symphony IL-6 Test has been accepted for presentation at the 2026 SAEM Annual Meeting. The study evaluates IL-6 levels in sepsis patients and their correlation with organ dysfunction. This research could enhance the understanding of IL-6 as a biomarker for critical care conditions.
Read more →BJDXBluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
Bluejay Diagnostics provided a corporate update regarding its Symphony platform and 2026 strategic outlook. The company confirmed progress in its SYMON II clinical study and ongoing manufacturing readiness efforts, positioning itself for future commercial production. Bluejay is focused on enhancing manufacturing and supply chain robustness while also seeking to raise additional capital as part of its growth strategy. Despite some financial challenges in the past year, the company remains optimistic about its future contributions to patient care in critical settings.
Read more →BJDXBluejay Diagnostics Announces All Prefunded Warrants Now Exercised
Bluejay Diagnostics announced that all prefunded warrants from its October 2025 private placement have been fully exercised as of February 19, 2026. The company now has around 972,000 shares outstanding and additional cash exercisable warrants for approximately 1.5 million shares. However, the Symphony System, aimed at improving sepsis diagnosis, still requires FDA regulatory clearance.
Read more →BJDXBluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
Bluejay Diagnostics has enrolled 545 patients in its SYMON™ II study, surpassing its target of 750. The company is advancing its manufacturing readiness and technology transfer initiatives into 2026. This progress is expected to strengthen regulatory positioning and support future partnerships as Bluejay transitions towards data analysis and commercialization.
Read more →BJDXBluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Bluejay Diagnostics has announced a 1-for-4 reverse stock split, effective January 29, 2026. This action will reduce the number of outstanding shares from approximately 2.83 million to about 708,533. The company aims to enhance its stock's marketability while maintaining its existing trading symbol on Nasdaq. Shareholders will receive cash payments for any fractional shares.
Read more →BJDXBluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
Bluejay Diagnostics has successfully completed the commercial-scale production of polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6). These antibodies meet internal performance criteria and are intended for use in the Symphony cartridge manufacturing process. The company has enough inventory to support the production of over nine million cartridges, although the Symphony system is still under development and requires regulatory approval.
Read more →BJDXBluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
Bluejay Diagnostics, Inc. has reported its financial results for Q3 2025, emphasizing progress in its clinical and operational initiatives. The company aims to redefine sepsis management through its Symphony platform, which is designed for rapid near-patient testing. However, the Symphony System is still awaiting FDA regulatory clearance before it can be marketed in the U.S.
Read more →BJDX▼ -10.7%on this news
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics has successfully closed a private placement, raising $4.5 million through the sale of 2.25 million shares and Series F warrants. The funds will be used for FDA approval processes and R&D activities. The Series F warrants have an exercise price of $1.75 and are immediately exercisable, expiring in five and a half years.
Read more →BJDX▲ +75.4%on this newsshared move
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
Bluejay Diagnostics has amended its agreements with SanyoSeiko to enhance the commercialization of its Symphony platform, a near-patient testing system for sepsis management. The partnership will allow SanyoSeiko to provide comprehensive manufacturing support, including hardware and software updates, and quality control. This collaboration aims to secure high-quality production capacity and facilitate broader clinical validation.
Read more →BJDX▲ +75.4%on this newsshared move
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics has announced a successful agreement for a private placement of 2,250,000 shares of common stock and Series F warrants totaling $4.5 million. The proceeds from this offering will be directed towards obtaining FDA approval and furthering research and development efforts. Closing of the placement is expected shortly, but the issued securities will not be registered under current securities laws, imposing restrictions on their sale.
Read more →About Bluejay Diagnostics, Inc.
Headquarters360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA, 01720
BIOPHARMAWATCH ELITE PLUS
Trade the next BJDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime